Mediwound (MDWD)
NASDAQ:MDWD
Want to see MDWD full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.76Last Year’s EPS
-1.23Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mix of positive strategic progress (clinical advancement for EscharEx, broad industry collaborations, strong government backing for NexoBrid via BARDA, and improved gross margin) alongside notable near-term financial and operational challenges (sharp Q1 revenue decline, higher R&D and losses, enrollment pacing issues, regulatory/ manufacturing implementation work, and reimbursement headwinds). Management reaffirmed full-year revenue guidance and outlined specific remediation steps (patient assistance, EMA actions), but near-term execution and cash consumption remain areas to watch.Company Guidance
EscharEx Phase III Progress and Expanded Clinical Program
Enrollment ongoing in global Phase III VALUE study with >30 active sites across the U.S., Europe and Israel and ~40 sites expected to be active within weeks; interim sample size reassessment and enrollment completion targeted by end of Q1 2027. Additional EscharEx development: DFU Phase II and investigator-initiated pressure ulcer study planned H2 2026, head-to-head Phase II vs collagenase planned, and required PK/human factors studies slated to start H2 2026.
Broad Industry Collaborations for EscharEx
Expanded collaboration network includes Medline (joining this quarter), Coloplast/Kerecis, Convatec, Essity, Mölnlycke, Solventum, B. Braun and MIMEDX — effectively covering major advanced wound care players; Medline to supply Marathon skin protectant for upcoming DFU trial.
Strong Strategic and Government Support for NexoBrid
Vericel awarded a 10-year BARDA contract valued up to $197M (to begin procurement and development H2 2026), building on ~$138M previously received from BARDA/Department of War over past decade; continued commercial adoption and guideline recognition (new national recommendations in Japan and U.K. added to WHO and several countries).
Manufacturing Progress and Regulatory Work Underway
Completed EMA pre-audit for expanded NexoBrid manufacturing facility; identified operational modifications being implemented with expected completion in H2 2026. U.S. inspection by FDA planned early 2027 following EMA/other agency activities.
Gross Margin Improvement Despite Revenue Drop
Q1 2026 gross profit $0.3M with gross margin 21.9% vs Q1 2025 gross margin 18.7% — margin improved by ~3.2 percentage points despite lower revenue, indicating cost or mix improvements.
Reaffirmed Full-Year 2026 Revenue Guidance
Company reaffirmed 2026 revenue guidance of $24M to $26M, expecting revenue to be weighted to the second half of the year driven primarily by government-related procurement and development services.
MDWD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MDWD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 27, 2026 | $16.68 | $14.33 | -14.09% |
Mar 05, 2026 | $17.60 | $17.45 | -0.85% |
Nov 20, 2025 | $17.86 | $16.86 | -5.60% |
Aug 14, 2025 | $18.75 | $18.57 | -0.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mediwound (MDWD) report earnings?
Mediwound (MDWD) is schdueled to report earning on Aug 19, 2026, Before Open (Confirmed).
What is Mediwound (MDWD) earnings time?
Mediwound (MDWD) earnings time is at Aug 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MDWD EPS forecast?
MDWD EPS forecast for the fiscal quarter 2026 (Q2) is -0.76.